Biohaven Pharma (BHVN) Tops Q2 EPS by 31c

Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($1.63), $0.31 better than the analyst estimate of ($1.94).

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Klarna shares tumble on weak full-year revenue guidance
• Corporación América Airports S.A. (CAAP) Misses Q2 EPS by 18c